October is Breast Cancer Awareness Month, and we at ConcertAI would like to recognize all those who are affected by this disease, and thank those who work to drive progress in breast cancer detection and treatment. We are deeply committed to advancing breast cancer research through innovative AI-driven data solutions that enhance precision medicine, accelerate clinical trial processes, and improve patient outcomes. Take a moment to learn more about several recent publications that draw on our data, solutions, and expertise to help drive progress in this critical area: Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States https://hubs.ly/Q02R_wVn0 Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis https://hubs.ly/Q02R_yk20 Quantification of information gained by linking claims data to an EHR cohort of US metastatic breast cancer (mBC) patients https://hubs.ly/Q02R_nMQ0 Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States https://hubs.ly/Q02R_l790 Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients https://hubs.ly/Q02R_tDg0 #BreastCancer #BreastCancerAwarenessMonth #Research #RWD #AI
ConcertAI
Biotechnology Research
Cambridge, Massachusetts 38,474 followers
Accelerating insights and outcomes for patients through leading RWD, AI technology and scientific expertise.
About us
The fastest growing AI-powered SaaS data company in healthcare.
- Website
-
https://concertai.com/
External link for ConcertAI
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Specialties
- Real World Data, Precision Medicine, RWE, Artificial Intelligence, biopharma, Clinical Trials, Real World Evidence, SaaS, Patient Access, Patient Outcomes, Patient Insights, Technology, Scientific Expertise, Biomedical Innovators, Leading RWE, Clinical Development, and Enterprise Data
Locations
Employees at ConcertAI
Updates
-
ConcertAI welcomes James Salitan as our new General Counsel. With over 25 years of experience leading legal and compliance teams in healthcare and technology, James brings significant expertise to our team. His addition will support our ongoing efforts to innovate in AI and real-world data solutions. Learn more about James' experience below: https://hubs.ly/Q02RMN3W0 #AIInnovation #HealthcareTech #hiring #LifeSciences
-
Join ConcertAI at National Association of Specialty Pharmacy (NASP) 2024 Annual Meeting to discover how our Specialty Data Aggregation is a leading solution designed to support the lifecycle of specialty pharmaceutical products from launch through post-launch management. By centralizing and analyzing data related to drug distribution and pharmacy performance, ConcertAI enables pharmaceutical companies to optimize their strategies, monitor market dynamics, and ensure that patients receive timely therapy support. Ready to see how ConcertAI can transform your specialty pharmacy strategy? Book a meeting with one of our experts attending NASP and take the first step towards data-driven success: https://hubs.ly/Q02Rx_1Z0 Ned Bement, Yash Shah, Sharilyn Star, Cameron Bailey #NASP2024 #SpecialtyPharmacy #PharmaData #HealthcareInnovation #PatientCare
-
On World Cancer Research Day, we celebrate the remarkable contributions of ConcertAI's dedicated team, who work tirelessly to advance cancer research. Our team's commitment to innovation is at the heart of our mission to enhance cancer care and improve patient outcomes. Through our groundbreaking research and development of CARAai, we are not just advancing science through innovation; we are deeply committed to maintaining patient centricity, ensuring that every breakthrough we achieve brings us closer to health equity and improved quality of life for people living with cancer. Interested in learning more about ConcertAI's research publications? Visit our publication library: https://hubs.ly/Q02QX38r0 Join our team to help drive progress in cancer prevention, diagnosis, and treatment. https://hubs.ly/Q02QX36y0
-
In this unique patient experience episode of The ConcertAI Podcast, host Jeff Elton sits down with ABC's Senior National Correspondent, Steve Osunsami, to discuss the critical importance of prostate cancer screening and awareness. Steve shares his personal patient journey with prostate cancer, from initial diagnosis at age 41 to treatment and recovery. He highlights the significance of early detection, particularly for high-risk groups such as African American men, and the life-saving potential of regular PSA testing. Through his candid storytelling, Steve addresses the challenges men face regarding prostate cancer and advocates for increased awareness and proactive health measures. His message is a powerful reminder of the importance of self-advocacy and the need for tailored healthcare guidelines to better serve diverse populations. We invite you to take a listen at your leisure on your preferred platform: Apple Podcasts: https://hubs.ly/Q02Q6v7d0 Spotify: https://hubs.ly/Q02Q6k5q0 #oncology #healthcare #realworlddata #ConcertAIPodcast #podcast #prostatecancer
-
ConcertAI will be at BioTechX USA this week in Pennsylvania to showcase how our latest CARAai advancements are transforming drug discovery and development in oncology. Experience firsthand on how the power of our AI and large language models (LLMs) enhance big data applications, driving pivotal breakthroughs and fostering vital collaborations across pharma, academia, and clinicians. Don’t miss ConcertAI team members Julie Neale & Seungtaek Lee at this premier biotechnology event where innovation meets opportunity. Set up a meeting today: https://hubs.ly/Q02PZvw_0 #AI #GenAI #Innovation #LLMs #BioTechnology #Biotech
-
This Monday at ESMO - European Society for Medical Oncology Congress, Novartis will be presenting a poster using ConcertAI's Patient360™ Breast data that dives into real-world insights from the NATALEE and monarchE eligible populations. Real-world evidence is essential in shaping the future of oncology. By examining the eligibility criteria of NATALEE and monarchE studies, we can better understand how these trials translate to everyday clinical practice. This research not only highlights the diversity of patient populations but also emphasizes the importance of personalized medicine in breast cancer care. Don’t miss the opportunity to engage with us at ESMO 2024! Our team is eager to share insights and discuss the implications of our work with fellow researchers, clinicians, and advocates in the oncology community. Learn more about this study by clicking the link below: https://hubs.ly/Q02PWfJ00 #ESMO24 #BreastCancer #RealWorldEvidence #PatientCare #OncologyResearch
-
Experience the excitement of ESMO - European Society for Medical Oncology Congress with our Strategic Account Manager, Joshua W. Murphy. Josh is looking forward to re-engaging with global researchers and discussing how ConcertAI's leading-edge AI solutions are transforming patient care. Feel the energy of innovation in Barcelona and discover how ConcertAI is making strides in predictive and Gen AI to improve patient outcomes. Set up a meeting today: https://hubs.ly/Q02PVrDG0 #ESMO24 #HealthcareInnovation #GlobalResearch
-
Congratulations to our hard working researchers, alongside our talented collaborators on having their research presented this Saturday at this year’s ESMO - European Society for Medical Oncology conference! Our poster dives deep into the real-world second-line outcomes of Non-Small Cell Lung Cancer (NSCLC) patients who have received first-line chemotherapy combined with immunotherapy. Utilizing ConcertAI's innovative Patient360™ NSCLC dataset, we’ve gathered insightful data that sheds light on patient experiences and treatment effectiveness in a real-world setting. Learn more about this study by clicking the link below: https://hubs.ly/Q02PQMFR0 Join us as we share valuable insights that could help shape future treatment strategies and improve patient outcomes. This research not only highlights the potential benefits of combining therapies but also emphasizes the importance of real-world data in understanding the complexities of NSCLC treatment. Meet with one of our attending team members to discuss how we can work together to enhance patient care in NSCLC. Let’s push the boundaries of cancer care! https://hubs.ly/Q02PQQb00 #ESMO24 #NSCLC #Immunotherapy #CancerResearch #HealthcareInnovation #LungCancerAwareness
-
Join Mike Rossi at ESMO - European Society for Medical Oncology Congress 2024 for a glimpse into the future of oncology! As VP of Translational & Multimodal RWE Solutions, Mike is inspired by the forward-looking nature of ESMO, showcasing clinical trials that highlight this year's achievements and set the stage for future advancements. Discover how ConcertAI leverages the largest clinical cloud of integrated clinico-genomic data to propel oncology forward. Set up a meeting today: https://hubs.ly/Q02PJymj0 #ESMO24 #ClinicalTrials #Oncology